PHARMACOVIGILANCE

Serious side effects force a third of diabetics to quit...

  The side effects of the world's most commonly-prescribed diabetes drug are so severe that around a third of patients stop taking it, a new study has...

Half of over-65s taking five or more prescription drugs a...

Half the population of over-65s is taking at least five different prescription drugs every day, and some are taking as many as 23, a new study has discovered. The...

Regulator hid dangers of epilepsy drug for 40 years

    Drug regulators knew an epilepsy drug could cause birth abnormalities if a woman took it while she was pregnant, but didn't alert the public...

Young women still being prescribed thalidomide

Thalidomide, the morning sickness drug that caused appalling birth defects in more than 10,000 babies in the 1960s, is still being prescribed to young women who become pregnant—and three women...

Someone takes a drug wrongly every 21 seconds (that's 10.5...

Pharmaceuticals are dangerous enough as it is—but when they're taken incorrectly, they can be lethal. It's a common problem, with someone in the US reporting a serious medication error every...

Depression overdiagnosed by questionnaire developed by drug company

People are being diagnosed with depression with a simplistic point-scoring questionnaire that was developed by the drug company that has some of the leading antidepressant brands, and so is most...

One in three new drugs have serious—and sometimes deadly—safety issues

There's something seriously wrong with our drug approval processes. One in three drugs that pass all the usual checks before being given a licence are unsafe, and are causing serious—and...

New drugs aren't being properly tested for their safety or...

New 'breakthrough' drugs are often being allowed onto the market as safe and effective treatments with minimal evidence—and drug companies are failing to provide any good research even five years...

Statins raise type 2 diabetes risk by 60 per cent

  Cholesterol-lowering statins do raise the risk of type 2 diabetes, a major new review has confirmed. The risk can rise by as much as 60 per...
Indietro12Avanti
EMA - Events


Events

12th Pharmacovigilance stakeholder forum, European Medicines Agency, London, UK, From:...

This forum brings together regulators with patients, healthcare professionals and industry, to take stock of what we have achieved and what needs to be the focus over the coming years.

Third industry stakeholder platform on research and development support, European...

This third meeting between regulators and representatives of industry stakeholder organisations addresses all areas of product-development support, including scientific advice, specifics for paediatric and orphan medicines and support for innovation....

European Medicines Agency (EMA) Human Scientific Committees' Working Parties with...

This Patients' and Consumers' Working Party (PCWP) plenary meeting will include discussions on patient engagement along the regulatory lifecycle and visibility of patient input throughout scientific procedures. Feedback will...
EMA - News and press releases


News and press releases

News and press releases: Meeting highlights from the Committee...

CHMP elects new chair and recommends thirteen medicines for approval

News and press releases: Valsartan: review of impurities extended...

A batch of losartan found to contain low levels of NDEA

News and press releases: New gene therapy for rare...

Luxturna is the first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene
EMA - Public consultations


Ongoing public consultations

Scientific guideline: Reflection paper on resistance in ectoparasites, draft:...

The Committee adopted a new draft reflection paper on ectoparasitic resistance (EMA/CVMP/EWP/310225/2014) for a 11-month period of public consultation. The reflection paper aims to give an overview of the currently...

Scientific guideline: Reflection paper on the use of aminopenicillins...

The objective of this document is to review available information on the use of aminopenicillins and their beta-lactamase inhibitor combinations in veterinary medicines in the EU, their effect on the...

Regulatory and procedural guideline: Draft guideline on the summary...

The guideline, which was developed to encourage optimal use and to minimise selection of antimicrobial resistance (AMR), was revised in order to improve consistency of the summary of product characteristics...
EMA - Vacancies


Vacancies

Discontinuation of vacancies RSS feed - visit our Careers section

Please note that from January 2018, EMA will publish vacancy notices on its [email protected] portal and will no longer update this vacancies RSS feed. For more information, please click on...